MONMOUTH JUNCTION, N.J.,
Feb. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq
CM: INSM), a biopharmaceutical company, will host a conference call
on Tuesday, March 13th, 2012, at
8:30 AM ET, to discuss its financial
results for the fourth quarter and year-end 2011. Insmed
intends to issue its quarterly and year-end financial results press
release before the market opens on March
13th.
To participate in the live conference call, please dial
800-798-2864 (U.S. callers) or 617-614-6206 (international), and
provide passcode 48373405. A live webcast of the call will
also be available at
http://www.media-server.com/m/p/xfhdp2ne. Please allow extra
time prior to the webcast to register, download and install any
necessary audio software.
The webcast will be archived for 30 days, and a telephone replay
of the call will be available for seven days, beginning at
10:30 AM ET on March 13th, at 1-888-286-8010 (U.S. callers) or
1-617 801-6888 (international), using passcode 11615475.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on
the development of innovative inhaled pharmaceuticals for the
site-specific treatment of serious lung diseases. Insmed's
primary focus is on the development of inhaled antibiotic therapy
delivered via proprietary advanced liposomal pulmonary technology
in areas of high unmet need. For more information, please
visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Investors are cautioned that such statements in this
release, including statements relating to our financial position,
results of operations, the status and the results of preclinical
studies and clinical trials and preclinical and clinical data
described herein, the timing of responses to information and data
requests from FDA, the development of our products, and the
business strategies, plans and objectives of management, constitute
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated by the forward-looking statements. Our results
may be affected by such factors as the receipt and timing of FDA
and other regulatory reviews and approvals, if at all, competitive
developments affecting our product development, delays in product
development or clinical trials, and patent disputes involving
currently developing products. The risks and
uncertainties include, without limitation, we may experience
unexpected regulatory actions, delays or requests, our future
clinical trials may not be successful, we may be unsuccessful in
developing our product candidates or receiving necessary regulatory
approvals, we may experience delays in our product development or
clinical trials, our product candidates may not prove to be
commercially successful, our expenses may be higher than
anticipated and other risks and challenges detailed in our filings
with the U.S. Securities and Exchange Commission, including our
Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on
Form 10-Q for the quarter ended September
30, 2011. Investors are cautioned not to place undue
reliance on any forward-looking statements which speak only as of
the date of this release. We undertake no obligation to
publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
Investor
Relations Contact:
Brian
Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.com
Media
Contact:
Irma
Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com
|
SOURCE Insmed Incorporated